Resuming Anticoagulants After Hematuria in Patients with Impaired Renal Function

Immediate Management and Anticoagulation Resumption

The American College of Cardiology recommends that anticoagulation can often be continued without interruption in patients with minor, self-limiting hematuria, though even minor bleeding predicts subsequent major bleeding risk 1
The British Society of Gastroenterology and European Society of Gastrointestinal Endoscopy recommend resuming DOACs 24 hours after hemostasis for low bleeding risk scenarios, and 48-72 hours after hemostasis for high bleeding risk scenarios 2, 3

The American College of Cardiology recommends resuming warfarin at usual maintenance dose once hemostasis is established, and considering bridging with LMWH if high-dose vitamin K was used for reversal 1, 5
For dabigatran, the recommended dose is contraindicated if CrCl <30 mL/min, and a reduced dose of 110-150 mg once daily is recommended for the first 2-3 days, then 150 mg twice daily for CrCl 30-50 mL/min 2, 3, 6
For rivaroxaban, a reduced dose of 10 mg once daily is recommended for the first 2-3 days, then 20 mg once daily 3
Apixaban is the preferred DOAC in moderate renal impairment due to lower renal clearance, and a reduced dose of 2.5 mg twice daily is recommended for the first 2-3 days, and permanently if the patient has ≥2 of: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL 3, 7

The Journal of the American College of Cardiology recommends monitoring hemoglobin every 4-6 hours initially until stable, and reassessing renal function before resuming DOACs 4
The British Society of Gastroenterology and European Society of Gastrointestinal Endoscopy recommend preferring LMWH or DOACs over unfractionated heparin or warfarin to minimize recurrence risk 2
The Gut journal recommends balancing thrombotic risk against bleeding risk when determining timing of resumption, and considering patient's CHADS₂ score and indication for anticoagulation 2, 3, 4